MOTS-c is produced inside mitochondria and translocates to the nucleus under metabolic stress, where it activates AMPK — the cell's central energy-sensing pathway. In animal studies, this translates to improved insulin sensitivity, resistance to diet-induced obesity, and exercise-mimetic effects on muscle metabolism. It's one of the few known signaling molecules that originates from mitochondrial, rather than nuclear, DNA.

• Endogenous production across tissues, particularly skeletal muscle, in response to metabolic stress
• Preclinical research: obesity, insulin resistance, age-related metabolic decline
• Sold online as an unregulated "research chemical," not through any legal human-use pathway

• Banned by WADA (2024) as a prohibited substance under its AMPK-activator, exercise-mimetic classification — a status few compounds in this atlas share
• Under FDA Pharmacy Compounding Advisory Committee (PCAC) review as of July 2026 to determine 503A compounding eligibility; even a favorable outcome would not constitute FDA drug approval
• No completed large-scale human efficacy trials exist; the only human data comes from a discontinued Phase 1 program on a synthetic analog, not the native peptide itself